LakeShore Biopharma Co., Ltd (NASDAQ:LSB) — Market Cap & Net Worth
Market Cap & Net Worth: LakeShore Biopharma Co., Ltd (LSB)
LakeShore Biopharma Co., Ltd (NASDAQ:LSB) has a market capitalization of $25.84 Million ($25.84 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #24353 globally and #5241 in its home market, demonstrating a -26.63% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying LakeShore Biopharma Co., Ltd's stock price $0.63 by its total outstanding shares 41212693 (41.21 Million). Also see LakeShore Biopharma Co., Ltd (LSB) total assets for a full breakdown of the balance sheet.
LakeShore Biopharma Co., Ltd Market Cap History: 2021 to 2026
LakeShore Biopharma Co., Ltd's market capitalization history from 2021 to 2026. Data shows change from $4.01 Billion to $25.84 Million (-44.09% CAGR). Also see LSB cash flow metrics for how efficiently the company converts equity into cash flow.
Index Memberships
LakeShore Biopharma Co., Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #697 of 976 |
Weight: LakeShore Biopharma Co., Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
LakeShore Biopharma Co., Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how LakeShore Biopharma Co., Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check LSB stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.04x
LakeShore Biopharma Co., Ltd's market cap is 0.04 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $4.01 Billion | $257.02 Million | -$191.83 Million | 15.59x | N/A |
| 2022 | $4.13 Billion | $502.95 Million | -$236.67 Million | 8.21x | N/A |
| 2023 | $210.60 Million | $687.20 Million | -$145.48 Million | 0.31x | N/A |
| 2024 | $142.60 Million | $573.42 Million | -$433.46 Million | 0.25x | N/A |
| 2025 | $25.84 Million | $614.96 Million | -$99.98 Million | 0.04x | N/A |
Competitor Companies of LSB by Market Capitalization
Companies near LakeShore Biopharma Co., Ltd in the global market cap rankings as of September 18, 2026. Review LakeShore Biopharma Co., Ltd (LSB) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to LakeShore Biopharma Co., Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
LakeShore Biopharma Co., Ltd Historical Marketcap From 2021 to 2026
Between 2021 and today, LakeShore Biopharma Co., Ltd's market cap moved from $4.01 Billion to $ 25.84 Million, with a yearly change of -44.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $25.84 Million | 0.00% |
| 2025 | $25.84 Million | -81.88% |
| 2024 | $142.60 Million | -32.29% |
| 2023 | $210.60 Million | -94.90% |
| 2022 | $4.13 Billion | +3.14% |
| 2021 | $4.01 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of LakeShore Biopharma Co., Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $25.84 Million USD |
| MoneyControl | $25.84 Million USD |
| MarketWatch | $25.84 Million USD |
| marketcap.company | $25.84 Million USD |
| Reuters | $25.84 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About LakeShore Biopharma Co., Ltd
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics for infectious diseases and cancer. Its product pipeline includes YSJA, a conventional rabies vaccine, which is in marketed stage; PIKA, a rabies vaccine, which is in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS… Read more